复发缓解型多发性硬化症中独立于复发活动的进展(PIRA)的标准化定义。

IF 20.4 1区 医学 Q1 CLINICAL NEUROLOGY
Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera
{"title":"复发缓解型多发性硬化症中独立于复发活动的进展(PIRA)的标准化定义。","authors":"Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera","doi":"10.1001/jamaneurol.2025.0495","DOIUrl":null,"url":null,"abstract":"Importance\r\nProgression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results.\r\n\r\nObjective\r\nTo compare various definitions of PIRA.\r\n\r\nDesign, Setting, and Participants\r\nThis cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments.\r\n\r\nExposure\r\nThree-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation).\r\n\r\nMain Outcome and Measure\r\nFor each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years).\r\n\r\nResults\r\nAmong 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months.\r\n\r\nConclusion and Relevance\r\nIncidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"121 1","pages":""},"PeriodicalIF":20.4000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.\",\"authors\":\"Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera\",\"doi\":\"10.1001/jamaneurol.2025.0495\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Importance\\r\\nProgression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results.\\r\\n\\r\\nObjective\\r\\nTo compare various definitions of PIRA.\\r\\n\\r\\nDesign, Setting, and Participants\\r\\nThis cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments.\\r\\n\\r\\nExposure\\r\\nThree-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation).\\r\\n\\r\\nMain Outcome and Measure\\r\\nFor each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years).\\r\\n\\r\\nResults\\r\\nAmong 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months.\\r\\n\\r\\nConclusion and Relevance\\r\\nIncidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.\",\"PeriodicalId\":14677,\"journal\":{\"name\":\"JAMA neurology\",\"volume\":\"121 1\",\"pages\":\"\"},\"PeriodicalIF\":20.4000,\"publicationDate\":\"2025-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamaneurol.2025.0495\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaneurol.2025.0495","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Importance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main Outcome and Measure For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years). Results Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and Relevance Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JAMA neurology
JAMA neurology CLINICAL NEUROLOGY-
CiteScore
41.90
自引率
1.70%
发文量
250
期刊介绍: JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and diseased nervous system. The Archives of Neurology & Psychiatry began publication in 1919 and, in 1959, became 2 separate journals: Archives of Neurology and Archives of General Psychiatry. In 2013, their names changed to JAMA Neurology and JAMA Psychiatry, respectively. JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信